Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC
BOSTON, November 8th, 2023 – Alloy Therapeutics, Inc., a biotechnology ecosystem company and Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today the formation of a non-exclusive, preferred service offering to drive translation from Discovery to CMC development and clinical material supply for ecosystem partners. The organizations are collaborating to provide a […]
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation. BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and […]
High Efficiency CAR Discovery Screening
Chimeric antigen receptor cell therapy (CAR-T, CAR-NK, etc.) is a promising therapeutic modality, but functional screening is a bottleneck for traditional two-step CAR-T discovery process of antibody binder discovery and CAR-T functional engineering. In this webinar, scientists at Alloy showcase their unique CAR discovery workflow that incorporates human antibody identification and characterization, mRNA-based CAR construct […]
Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners
Biotherapeutic discovery and development expert Michael Schmidt joins as CSO to manage an expansive roadmap of technical innovation across Alloy’s platforms, services, and company formation in six modalities. Alloy’s Martin Leach is promoted to COO to expand the company’s operational excellence and discovery services capacity for partners. BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, […]
Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicine
AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the AntiClastic ASO platform, to chair Alloy’s genetic medicines scientific advisory board (SAB). BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential. BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members […]
Alloy Therapeutics Unveils 2023 Innovation Roadmap Across Antibodies, TCRs, Bispecifics, and Genetic Medicines
— Alloy’s growing services portfolio reflects its commitment to empowering global scientific community with access to broad, foundational biologics discovery capabilities — BOSTON, MA; January 9, 2023—Alloy Therapeutics, a biotechnology ecosystem company, announced its 2023 roadmap of new discovery technologies and services across a range of biologic modalities. Alloy will support its community of 140+ partners […]
Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
— Partnership leverages Alloy’s high velocity antibody discovery offering to accelerate Normunity’s novel precision immuno-oncology pipeline — BOSTON, MA; November 17, 2022—Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
— Following a successful expansion from antibodies into T-cell receptors and genetic medicines, Alloy will broaden its pre-competitive discovery technology and discovery services to enable innovative new therapeutic formats — BOSTON, MA; October 03, 2022—Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala […]
Alloy Therapeutics Hires People Executive Trier Bryant as President of Venture Studio, 82VS
—Trier will lead operations and strategy of people-focused venture studio, supporting ecosystem of scientific entrepreneurs— BOSTON, MA; September 07, 2022–Alloy Therapeutics, a biotechnology ecosystem company, welcomes Trier Bryant as President of 82VS, Alloy’s affiliated venture studio. Trier is a strategic executive leader with distinctive tech, Wall Street, and military experience spanning 15 years, and brings a […]
